Minerva Neurosciences Reports $125.4 Million Net Loss in Latest Quarter

Minerva Neurosciences, Inc. reported significant financial challenges in its latest quarterly filing, revealing a net loss of $125.4 million for the three months ended March 31, 2026, compared to a loss of $3.8 million during the same period in 2025. The company's total expenses surged to $16.7 million, up from $3.9 million year-over-year, primarily driven by increased research and development costs associated with the initiation of a new Phase 3 clinical trial for its lead product candidate, roluperidone. The company’s accumulated deficit has now reached approximately $814.2 million, reflecting ongoing operational losses since its inception.

The financial performance highlights a stark increase in both research and development and general administrative expenses. Research and development expenses rose to $5.3 million from $1.4 million, while general and administrative expenses jumped to $11.4 million from $2.5 million, largely due to a one-time, non-cash charge of $6.6 million related to a settlement agreement with former President Geoffrey Race. The company also reported a substantial loss of $109.4 million related to changes in the fair value of its warrant liability, which significantly impacted its overall financial results.

Operationally, Minerva is focused on advancing its clinical programs, particularly the C19 trial for roluperidone, which aims to enroll 380 patients diagnosed with schizophrenia. The trial is designed to assess the efficacy of roluperidone in treating negative symptoms, with topline results expected in the second half of 2027. The company has also engaged in strategic financial maneuvers, including a private placement of Series A convertible preferred stock and warrants, which raised $80 million in gross proceeds in October 2025. As of March 31, 2026, the company had cash, cash equivalents, marketable securities, and restricted cash totaling approximately $78.2 million, which it believes will be sufficient to meet its operational commitments for at least the next twelve months.

Despite these efforts, Minerva has not yet generated any revenue from product sales, as none of its product candidates have received regulatory approval. The company continues to evaluate its drug development programs and may seek additional capital or collaborations to support its ongoing operations. The outlook remains cautious, with management anticipating continued operating losses and negative cash flows as it navigates the complexities of clinical trials and regulatory processes.